217 related articles for article (PubMed ID: 36243854)
1. PI3K Targeting in Non-solid Cancer.
Kim HN; Ogana H; Sanchez V; Nichols C; Kim YM
Curr Top Microbiol Immunol; 2022; 436():393-407. PubMed ID: 36243854
[TBL] [Abstract][Full Text] [Related]
2. Targeting PI3K Signaling in Acute Lymphoblastic Leukemia.
Sanchez VE; Nichols C; Kim HN; Gang EJ; Kim YM
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669372
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
4. CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway.
Cheng J; Li Y; Liu S; Jiang Y; Ma J; Wan L; Li Q; Pang T
FASEB J; 2019 Apr; 33(4):4755-4764. PubMed ID: 30592634
[TBL] [Abstract][Full Text] [Related]
5. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
6. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.
Schrader A; Popal W; Lilienthal N; Crispatzu G; Mayer P; Jones D; Hallek M; Herling M
Curr Cancer Drug Targets; 2014; 14(8):700-12. PubMed ID: 25348018
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.
Ding W; Knox TR; Tschumper RC; Wu W; Schwager SM; Boysen JC; Jelinek DF; Kay NE
Blood; 2010 Oct; 116(16):2984-93. PubMed ID: 20606160
[TBL] [Abstract][Full Text] [Related]
8. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Chapman CM; Sun X; Roschewski M; Aue G; Farooqui M; Stennett L; Gibellini F; Arthur D; Pérez-Galán P; Wiestner A
Clin Cancer Res; 2012 Apr; 18(7):1979-91. PubMed ID: 22351695
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
10. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
[TBL] [Abstract][Full Text] [Related]
11. Combined BCL-2 and PI3K/AKT Pathway Inhibition in
Holz C; Lange S; Sekora A; Knuebel G; Krohn S; Murua Escobar H; Junghanss C; Richter A
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674872
[TBL] [Abstract][Full Text] [Related]
12. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
13. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.
Tabe Y; Jin L; Tsutsumi-Ishii Y; Xu Y; McQueen T; Priebe W; Mills GB; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
Cancer Res; 2007 Jan; 67(2):684-94. PubMed ID: 17234779
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.
Kern D; Regl G; Hofbauer SW; Altenhofer P; Achatz G; Dlugosz A; Schnidar H; Greil R; Hartmann TN; Aberger F
Oncogene; 2015 Oct; 34(42):5341-51. PubMed ID: 25639866
[TBL] [Abstract][Full Text] [Related]
15. Blockade of FGF2/FGFR2 partially overcomes bone marrow mesenchymal stromal cells mediated progression of T-cell acute lymphoblastic leukaemia.
Tian C; Li Y; Wang L; Si J; Zheng Y; Kang J; Wang Y; You MJ; Zheng G
Cell Death Dis; 2022 Nov; 13(11):922. PubMed ID: 36333298
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
17. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
[TBL] [Abstract][Full Text] [Related]
18. Peptide hormone ELABELA promotes rat bone marrow-derived mesenchymal stem cell proliferation and migration by manipulating the cell cycle through the PI3K/AKT pathway under the hypoxia and ischemia microenvironment.
Chen X; Zhou C; Xu D; Liu X; Li S; Hou J; Zhang K; Zeng C; Zheng G; Wu H; Wu H; Wang W; Fu J; Wang T
Stem Cell Res Ther; 2022 Jan; 13(1):32. PubMed ID: 35090551
[TBL] [Abstract][Full Text] [Related]
19. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Aydin E; Faehling S; Saleh M; Llaó Cid L; Seiffert M; Roessner PM
Front Immunol; 2020; 11():595818. PubMed ID: 33552053
[TBL] [Abstract][Full Text] [Related]
20. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
